[go: up one dir, main page]

ES2192929B1 - Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones. - Google Patents

Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.

Info

Publication number
ES2192929B1
ES2192929B1 ES200100825A ES200100825A ES2192929B1 ES 2192929 B1 ES2192929 B1 ES 2192929B1 ES 200100825 A ES200100825 A ES 200100825A ES 200100825 A ES200100825 A ES 200100825A ES 2192929 B1 ES2192929 B1 ES 2192929B1
Authority
ES
Spain
Prior art keywords
pellets
applications
gastrorresistent
omeprazol
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100825A
Other languages
English (en)
Other versions
ES2192929A1 (es
Inventor
Luis Carvajal Martin
Juan Carlos Asensio Asensio
Francisco J. Sevilla Tirado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Belmac SA
Original Assignee
Laboratorios Belmac SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Belmac SA filed Critical Laboratorios Belmac SA
Priority to ES200100825A priority Critical patent/ES2192929B1/es
Publication of ES2192929A1 publication Critical patent/ES2192929A1/es
Application granted granted Critical
Publication of ES2192929B1 publication Critical patent/ES2192929B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento mejorado para la obtención de pellets de omeprazol estables y gastrorresistentes, pellets así obtenidos y aplicaciones. El procedimiento comprende: (a) selección y fabricación de "neutros"; (b) adhesión del principio activo a dichos neutros para obtener "núcleos activos"; (c) aislamiento de dichos núcleos activos para obtener "núcleos activos aislados"; y (d) recubrimiento de dichos núcleos activos aislados para obtener "núcleos activos gastrorresistentes". Dichos pellets son los referidos "núcleos activos gastrorresistentes" obtenidos por dicho procedimiento. Aplicación en medicina humana y veterinaria.
ES200100825A 2001-04-06 2001-04-06 Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones. Expired - Fee Related ES2192929B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200100825A ES2192929B1 (es) 2001-04-06 2001-04-06 Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100825A ES2192929B1 (es) 2001-04-06 2001-04-06 Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.

Publications (2)

Publication Number Publication Date
ES2192929A1 ES2192929A1 (es) 2003-10-16
ES2192929B1 true ES2192929B1 (es) 2005-02-16

Family

ID=29724673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100825A Expired - Fee Related ES2192929B1 (es) 2001-04-06 2001-04-06 Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.

Country Status (1)

Country Link
ES (1) ES2192929B1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
ES2047451B1 (es) * 1992-07-10 1994-10-01 Sint Quimica Sa Procedimiento para la preparacion de una composicion farmaceutica oral estable.
ES2087823B1 (es) * 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.

Also Published As

Publication number Publication date
ES2192929A1 (es) 2003-10-16

Similar Documents

Publication Publication Date Title
Waldvogel et al. First Artificial Receptor for Caffeine-A New Concept for the Complexation of Alkylated Oxopurines This work was supported by the Fonds der Chemischen Industrie (Liebig fellowships for SRW and CAS) and the Deutsche Akademie der Naturforscher Leopoldina/BMBF (postdoctoral fellowship for CAS). We are particularly grateful to Prof. Dr. Julius Rebek, Jr. for fruitful discussions and all his support for this project
TW200630326A (en) Chemical compounds
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
SE0100568D0 (sv) Compounds
GEP20063895B (en) Platinum derivative pharmaceutical formulations
AR025428A1 (es) Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asicomo eventualmente otros excipientes
BR0312563A (pt) Comprimido de lasofoxifeno e seu revestimento
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
ES2153820T3 (es) Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones.
ATE415817T1 (de) Agrochemische formulierungen
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
UY28733A1 (es) Compuestos quimicos
BRPI0411752A (pt) implantes subcutáneos apresentando liberação inicial limitada do princìpio ativo e liberação ampliada subseqüente linearmente variável do mesmo
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
BRPI0409532A (pt) composição farmacêutica, formulação liofilizada, método de fabricação de composição farmacêutica, método de fabricação de formulação liofilizada e artigo de fabricação
LT2006009A (en) Controlled release compositions of betahistine
SE0103819D0 (sv) Chemical compounds
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
ES2192929B1 (es) Procedimiento mejorado para la obtencion de pellets de omeprazol estables y gastrorresistentes, pellets asi obtenidos y aplicaciones.
BRPI0415870A (pt) comprimidos de baixa dose com rede de polìmeros
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
NO20024363D0 (no) Nye LHRH-antagonister, produksjon og anvendelse av disse som medikamant
ECSP045232A (es) Forma de dosificación oral, procedimiento para prepararla y uso de una base débil farmacéuticamente aceptable o una sal o solvato farmacéuticamente aceptable de la misma para preparar dicha forma de dosificación oral

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031016

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192929B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807